BIIL-260

• Description :

  BIIL-260 is a potent and long-acting orally active leukotriene B (4) receptor LTB4 antagonist, with anti-inflammatory activity. BIIL-260 interacts with the LTB4 receptor in a saturable, reversible, and competitive manner, has high affinity to the LTB4 receptor on isolated human neutrophil cell membranes with the Ki value of 1.7 nM[1].

• UNSPSC :

  12352005

• Target :

  Leukotriene Receptor

• Type :

  Reference compound

• Related Pathways :

  GPCR/G Protein

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/biil-260.html

• Smiles :

  N=C(N)C1=CC=C(C=C1)OCC2=CC=CC(COC3=CC=C(C=C3)C(C4=CC=C(C=C4)O)(C)C)=C2

• Molecular Formula :

  C30H30N2O3

• Molecular Weight :

  466.57

• References & Citations :

  [1]Birke FW, et al. In vitro and in vivo pharmacological characterization of BIIL 284, a novel and potent leukotriene B (4) receptor antagonist. J Pharmacol Exp Ther. 2001 Apr;297 (1) :458-66.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [204974-93-6]